CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 34 enrolled
Drug / intervention
Zoledronic acid +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00799266
NCT00799266Phase 3Completed

A Multicenter, Randomized, Double-blind, Placebo Controlled Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly Compared to Placebo in Osteoporotic Children Treated With Glucocorticoids.

Novartis Pharmaceuticals·interventional·Posted Nov 27, 2008·Updated Sep 2, 2020

In Brief

A Phase 3 clinical trial evaluating Zoledronic acid and Placebo for Osteoporosis. Completed, enrolled 34 participants across 12 sites in 6 countries.

Detailed Summary

This study was designed to evaluate the efficacy and safety of zoledronic acid compared to placebo in osteoporotic children treated with glucocorticoids

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis
CountriesAustralia, Canada, Hungary, Russia, South Africa, United Kingdom
Collaborators--

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 27, 2008
Enrollment StartDec 4, 2008
Primary CompletionMar 5, 2018
TodayJul 2, 2026
Enrollment to primary: 9.3 yearsPosted 17.6 years ago

Interventions

Zoledronic aciddrug

intravenous infusion

Placebodrug

intravenous infusion